Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06665997 · ClinicalTrials.gov registry record · Phase 4

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

A Phase 4 study of Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episode in Sickle Cell Disease, sponsored by University of Pennsylvania.

Recruiting
Registry status
Phase 4
Development phase
65
Enrollment target
2
Study locations

NCT06665997 is a Phase 4 study of Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episode in Sickle Cell Disease that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 65 participants, below the 398-participant average among 4 other Sickle Cell Disease (SCD) trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06665997, a Phase 4 study of Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episode in Sickle Cell Disease, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
Phase 4
Development phase
65 participants
Enrollment target
2
Study locations

Study Summary

This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease. Participants in this study will be adult women with sickle cell disease who regularly experience sickle cell pain. They will complete a 3-month "baseline "with no use of hormonal contraception, and then a 3-month follow-up after receiving an injection of Depo-Provera. Participants will complete 6 to 7 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as complete remote weekly surveys and monthly home pregnancy tests.

Conditions Studied

Sickle Cell Disease (SCD) Vaso-Occlusive Pain Episode in Sickle Cell Disease

Interventions

  • DRUG Depot medroxyprogesterone acetate (DMPA)

Study Locations (2)

Georgia

  • Emory University - Atlanta

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2025-06-26
Est. Completion 2027-10
Phase Phase 4

Sponsor

University of Pennsylvania

1,423 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06665997

The ClinicalTrials.gov registry entry for NCT06665997 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 398-participant average among 4 other Sickle Cell Disease (SCD) trials with a reported enrollment target (84% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sickle Cell Disease (SCD) appearing as the primary indexed condition, and to 1 intervention - of which Depot medroxyprogesterone acetate (DMPA) is the first listed.

NCT06665997 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06665997 about?

NCT06665997 is a clinical study titled "Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease". This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease. Participants in this study will be adult women with sickle cell disease who regularly experience sickle ...

What is the current status of trial NCT06665997?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2025-06-26. Estimated completion is 2027-10.

What conditions does trial NCT06665997 study?

This clinical trial studies the following conditions: Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease.

What interventions are being tested in trial NCT06665997?

The interventions under investigation include: Depot medroxyprogesterone acetate (DMPA) (DRUG).

Who is sponsoring clinical trial NCT06665997?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06665997 being conducted?

This trial has 2 study locations across Georgia, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease (SCD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease (SCD)

All registered trials for this condition

Vaso-Occlusive Pain Episode in Sickle Cell Disease

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.